AAPG
NASDAQAscentage Pharma Group International
$23.89-2.47 (-9.37%)
News25/Ratings8
Price$23.89-4.31 (-15.28%)
2026-01-212026-04-24
News · 26 weeks74-68%
2025-11-022026-04-26
Mix4390d
- Insider23(53%)
- SEC Filings10(23%)
- Offering8(19%)
- Analyst2(5%)
Latest news
25 items- ANALYSTDeutsche Bank initiated coverage on Ascentage Pharma with a new price targetDeutsche Bank initiated coverage of Ascentage Pharma with a rating of Buy and set a new price target of $40.00
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstrac
- INSIDERSEC Form 4 filed by Misra Veet4 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERSEC Form 3 filed by new insider Misra Veet3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Cao Jin3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual MeetingROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA. These posters feature three of the Company's drug candidates, Olverembatinib (HQP1351), a novel BCR-ABL inhibitor; APG-2449, a FAK/ALK/ROS1 triple tyrosine kinase
- INSIDERSEC Form 3 filed by new insider Cao Jin3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business UpdatesProduct sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisaftoclax since launch during last five months of 2025 were US$10.1 million (RMB 70.6 million)Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMAChinese (Mandarin) investor event with simultaneous conference call and webcast at 10:00 am HKT on March 26, 2026 / 10:00 pm EDT on March 25, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on March 26, 2026 ROCKVILLE, Md. and SUZHOU, China, March
- INSIDERSEC Form 3 filed by new insider Zhai Yifan3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wei Ren3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Ye Changqing3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Yu Debra3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Lu Simon Dazhong3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Lu Simon Dazhong3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Sidransky David3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wang Shaomeng3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Lippman Marc E3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERSEC Form 3 filed by new insider Knapp Thomas J3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Yang Dajun3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Bozilenko Marina3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ye Changqing3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)